XDR tuberculosis in South Africa: old questions, new answers

The Lancet

Volumn 375, Issue 9728, 2010, Pages 1760-1761

  Migliori, Giovanni Battista ^a   Sotgiu, Giovanni ^b  

^a IRCCS   (Italy)

^b UNIVERSITY OF SASSARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIRETROVIRUS AGENT; CAPREOMYCIN; ISONIAZID; KANAMYCIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN;

ARTICLE; BODY MASS; CULTURAL FACTOR; DRUG EFFICACY; EARLY INTERVENTION; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HEALTH CARE AVAILABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MORTALITY; OUTCOME ASSESSMENT; POVERTY; PRIORITY JOURNAL; PROGNOSIS; PSYCHOSOCIAL CARE; SOUTH AFRICA; UNSPECIFIED SIDE EFFECT;

EID: 77952548691     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)60593-4     Document Type: Note

References (14)

1. Dheda K., Shean K., Zumla A., et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet (2010) 10.1016/S0140-6736(10)60492-8 published online May 19.
2. Migliori G.B., Richardson M.D., and Lange C. Of blind men and elephants: making sense of extensively drug-resistant tuberculosis. Am J Respir Crit Care Med 178 (2008) 1000-1001
3. Saxe J.G. The poems of John Godfrey Saxe (1868), Ticknor and Fields, Boston
4. Migliori G.B., Besozzi G., Girardi E., et al. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J 30 (2007) 623-626
5. Keshavjee S., Gelmanova I.Y., Farmer P.E., et al. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet 372 (2008) 1403-1409
6. Sotgiu G., Ferrara G., Matteelli A., et al. Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J 33 (2009) 871-881
7. Bonilla C.A., Crossa A., Jave H.O., et al. Management of extensively drug-resistant tuberculosis in Peru: cure is possible. PLoS ONE 3 (2008) e2957
8. Gandhi N.R., Moll A., Sturm A.W., et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368 (2006) 1575-1580
9. Gandhi N.R., Shah N.S., Andrews J.R., et al. HIV co-infection in multidrug- and extensively drug resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med 181 (2010) 80-86
10. Lönnroth K., Jaramillo E., Williams B.G., et al. Drivers of tuberculosis epidemics: the role of risk factors and social determinants. Soc Sci Med 68 (2009) 2240-2246
11. Raviglione M.C., and Uplekar M.W. WHO's new Stop TB Strategy. Lancet 367 (2006) 952-955
12. WHO. Interim policies on collaborative TB/HIV activities (2004). http://whqlibdoc.who.int/hq/2004/who_htm_tb_2004.330.pdf (accessed May 5, 2010).
13. Tuberculosis Coalition for Technical Assistance. International Standards for Tuberculosis Care (ISTC) (2009), Tuberculosis Coalition for Technical Assistance, The Hague. http://www.istcweb.org/documents/ISTC_Report_2ndEd_Nov2009.pdf (accessed May 5, 2010).
14. WHO. Patients' charter for tuberculosis care (2006), World Care Council. http://www.who.int/tb/publications/2006/patients_charter.pdf (accessed May 5, 2010).